セッション詳細
一般口演 食道3 術前治療・予後因子
2025年10月24日(金) 10:50 〜 11:50
第1会場 (大阪国際会議場 5F 大ホール)
座長：土岐 祐一郎(大阪大学 消化器外科), 塩崎 敦(京都府立医科大学 外科学教室 消化器外科部門)
[EOP3-1]Immunochemotherapy versus chemoradiotherapy as induction therapy followed by conversion surgery for unresectable stage cT4 esophageal squamous cell carcinoma【優秀演題賞】
Dong Tian1, Kaiyuan Jiang2, Junjie Wang3 (1.Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China, 2.Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan, 3.Department of Thoracic Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China)
[EOP3-2]Tislelizumab Plus Chemotherapy versus Triplet Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-III Esophageal Squamous Cell Carcinoma：Preliminary Results of a Randomized Phase II Trial
Lilan Zhao1, Zijie He1, Zhaojun Yu1, Yangyun Huang1, Zhijun Huang2, Jie Xu2, Qingfeng Zheng3, Xiaojie Pan1, Wenshu Chen1 (1.Department of Thoracic Surgery, Fuzhou University Affiliated Provincial Hospital, Fuzhou University, Fuzhou, Fujian Province, China, 2.Department of Gastrointestinal and Esophageal Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China, 3.Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China)
[EOP3-3]Long-Term Survival and Treatment Patterns in Resectable Esophageal Squamous Cell Carcinoma in East Asia：A Comprehensive Study from the International Esodata Study Group（Dragon Study）
Xuefeng Leng1, Koshiro Ishiyama2, Xufeng Guo3, Ian Wong4, Seong Yong Park5, MadhanKumar Kuppusamy6, Hong Kwan Kim5, Simon Law4, Yongtao Han1, Donald Low6, Hiroyuki Daiko2 (1.Sichuan Cancer Hospital ＆ Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China（UESTC）, Chengdu, China, 2.National Cancer Center Hospital, Tokyo, Japan, 3.Shanghai Chest Hospital, Shanghai, China, 4.Queen Mary Hospital, Hong Kong University, Hong Kong, China, 5.Samsung Medical Center, Seoul, Korea, 6.Virginia Mason Medical Center, Seattle, USA)
[EOP3-4]食道癌NAC-DCF施行例における転移リンパ節の早期縮小率の有用性
萩 隆臣1,2, 白石 治2, 寺田 長央2, 山田 淳史2, 好田 匡志2, 中西 智也2, 平木 洋子2, 加藤 寛章2, 安田 篤2, 新海 政幸2, 今野 元博2, 安田 卓司2 (1.大阪大学大学院医学系研究科 消化器外科学, 2.近畿大学医学部 外科学教室 上部消化管部門)
[EOP3-5]Intratumoral and Peritumoral Radiomics-based Machine Learning Models for the Survival Prediction in Esophageal Squamous Cell Carcinoma after Surgery
Zhi Qiang Deng1, Haoji Yan2, Chen Yang3, Hong Tao Tang4, Dong Tian1 (1.Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China, 2.Department of General Thoracic Surgery, Juntendo University School of Medicine, Tokyo, Japan, 3.College of Medical Imaging, North Sichuan Medical College, Nanchong, China, 4.Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China)
[EOP3-6]Comparison of the prognostic value of LODDS and N stage for esophageal squamous cell carcinoma patients treated with neoadjuvant immunochemotherapy：a multicenter retrospective study
Feng Wang, Yi Han, Lei Yang, Yan Dongjie (Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University；Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China)